KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Net Margin (2016 - 2025)

Historic Net Margin for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to 20.1%.

  • Alnylam Pharmaceuticals' Net Margin rose 423800.0% to 20.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.65%, marking a year-over-year increase of 175100.0%. This contributed to the annual value of 12.37% for FY2024, which is 117100.0% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Net Margin stood at 20.1%, which was up 423800.0% from 8.57% recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Net Margin high stood at 20.1% for Q3 2025, and its period low was 191.6% during Q1 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Net Margin value was 61.93% (recorded in 2022), while the average stood at 65.5%.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Net Margin surged by 1732700bps in 2023, and later plummeted by -1782600bps in 2025.
  • Alnylam Pharmaceuticals' Net Margin (Quarter) stood at 99.97% in 2021, then soared by 38bps to 61.93% in 2022, then soared by 49bps to 31.35% in 2023, then surged by 55bps to 14.12% in 2024, then soared by 242bps to 20.1% in 2025.
  • Its Net Margin stands at 20.1% for Q3 2025, versus 8.57% for Q2 2025 and 191.6% for Q1 2025.